AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03412565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan will be administered as 9 mg/m\^2 orally in Cycles 1 to 9.
Study NCT03412565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone will be administered as 60 mg/m\^2 orally in cycles 1 to 9.
Study NCT03412565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib will be administered as 20 mg/m\^2 IV on Day 1 of Cycle 1 only then 70 mg/m\^2 IV on Days 8 and 15 of Cycle 1 and Days 1, 8 and 15 of Cycle 2 and thereafter until documented progression of disease, unacceptable toxicity, or end of study in D-Kd cohort.
Study NCT01789398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BF2.649
Description: BF2.649 is provided in capsules. Patients should take 1 capsules per day with a glass of water. They will be instructed to take 1 capsule in the morning (after waking up, before breakfast).
Study NCT01789398 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BF2.649
Description: BF2.649 is provided in capsules. Patients should take 1 capsules per day with a glass of water. They will be instructed to take 1 capsule in the morning (after waking up, before breakfast).
Study NCT04711161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRN-300
Description: A salt-inducible kinase (SIK) inhibitor
Study NCT04711161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Microtubule inhibitor
Study NCT04463069 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted physical activity
Description: This PA program was modified from an adapted physical activity (APA) program that designed for obesity management among adolescents with intellectual disability (ID). The aim of the APA program was to promote PA and health for people in special needs. In this study, the APA program was carefully designed based on a comprehensive pre-intervention assessment of each adolescent with ID, so that can be able to address their individual needs in learning and adaption. The APA program comprised three stages of APA training at school and each stage consisted of simple and fun endurance and strength-building exercise, at a frequency of two sessions per week, and lasting for about three months.
Study NCT04046614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nintedanib-nivolumab combination therapy
Description: Safety run-in - Dose finding stage The safety-run in phase will be designed as a standard 3+3 design for dose escalation/de-escalation and 3 to 6 patients will be enrolled in each cohort sequentially, depending on occurrence of dose limiting toxicities. The recommended phase 2 dose (RP2D) will be the highest dose in which the frequency of DLTs is less than 33% if no other safety or feasibility considerations prevail.~Expansion phase: Nintedanib RP2D + nivolumab 240 mg Q2W until progression of disease.
Study NCT04107025 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HELP
Description: Individual counseling were given to each intervention group participant. They were assisted with safety, emotional and mental support and referrals for health and financial assistance. Participants were also given handout to manage anxiety and panic situations during the legal procedures.
Study NCT01896791 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: Active Transcranial Direct Current Stimulation : the anode electrode is placed in the area of the motor cortex M1 C3 or C4 position of the dominant hemisphere (International 10-20 EEG System). The cathode electrode is placed over the contralateral supraorbital region to the anode electrode. Treatment time and intensity of the stimulus: tDCS: 2 mili Ampere, 20min, 10 days.
Study NCT01896791 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Stimulation
Description: Sham Stimulation- appliance off during the entire period without active stimulation, with the position of the electrodes in the same sites of active stimulation
Study NCT04452110 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonography
Description: Temporomandibular joint diseases of ultrasonography its effectiveness and reliability in diagnosis disadvantages in MR and other imaging methods be ruled out.
Study NCT00501904 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Study NCT04158934 — intervention group
Intervention type: BIOLOGICAL
Intervention: ADYNOVI/ADYNOVATE
Description: Participants will receive ADYNOVI/ADYNOVATE prescribed prophylactically by physicians based on their standard clinical practice and in accordance with the national SmPC.
Study NCT03438071 — intervention group
Intervention type: OTHER
Intervention: Videoconferencing
Description: Daily videoconference updates using Skype between parents of preterm infants hospitalized in NICU and the nurse taking care of their child, lasting 5 to 10 minutes, to check with her for the daily news and then see their child through the camera.
Study NCT01686997 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-en-Y Gastric Bypass
Study NCT02371915 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Videoconference follow-up
Description: Rheumatology visits to take place video videoconference with a physiotherapist present
Study NCT00575146 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TAVARLIN
Description: ketogenic diet, dietary supplementary products provided by TAVARLIN
Study NCT01783756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib ditosylate
Description: Given PO
Study NCT01783756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Given PO
Study NCT01783756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given PO
Study NCT01783756 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03225508 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Linear Ultrasound to Measure Diaphragmatic Movement
Description: A linear 10-12 MHz ultrasound probe will be used to determine diaphragmatic excursion, by examining the zone of apposition. Diaphragmatic excursion will be measured from end inspiration to end expiration. The measurement will be repeated twice, and an average of the two will be taken. The distance between the two external skin markings, one at the end of full expiration and one at the end of full inspiration will indicate the excursion of the diaphragm.
Study NCT03225508 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Curvilinear Ultrasound to Measure Diaphragmatic Movement
Description: A curvilinear 2-5 MHz ultrasound probe will be used to determine diaphragmatic excursion, by examining the dome of the diaphragm. M-mode will be used to image the motion of the diaphragm from end inspiration to end expiration. The measurement will be repeated twice, and an average of the two will be taken.
Study NCT03225508 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary function tests
Description: Bedside pulmonary function tests to measure forced vital capacity (FVC). The FVC measures the maximal volume of gas that can be expired as forcefully and rapidly as possible after a maximal inspiration to total lung capacity. This measurement will help determine if the patient has any obstructive or restrictive diseases of the airways. Three measurements will be taken.
Study NCT01451437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8242
Description: MK-8242 capsules, orally, once per day on Days 1-7 and Days 15-21 of each 28-day cycle (except Cycle 1 Day 7) up to a maximum of 12 cycles. Starting dose will be 30 mg and will be escalated in successive cohorts until maximum tolerated dose (MTD) is established. Beginning at a dose level of ≥120 mg total daily dose (TDD), the dosing regimen will switch to twice daily (BID). Amendment 4 added a 21-day dosing cycle in which MK-8242 would be given BID on Days 1-7 of each cycle, at the assigned dose level.
Study NCT03754478 — intervention group
Intervention type: OTHER
Intervention: Physical activity training
Description: subjects will enter a 3-month supervised physical activity program during which they will take part to supervised and unsupervised physical activity sessions. Type of physical activity will be selected among a number of available activities (aquagym, aerobics, resistance training, outdoors activities) based on individual needs and preferences); it will consist in 2 weekly supervised activity sessions during which participants will be instructed by a specialist in adapted physical activity, and 2-3 weekly session of unsupervised physical activity which will be performed according to detailed instructions regarding intensity and duration.
Study NCT03219970 — intervention group
Intervention type: DRUG
Intervention: Osimertinib
Description: 80mg oral daily
Study NCT00777153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib
Description: 30 mg/day, oral, until progression
Study NCT00777153 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cediranib
Description: 20 mg/day, oral, until progression
Study NCT00777153 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lomustine Chemotherapy
Description: 110 mg/m2 / Q6W, oral, until progression
Study NCT00777153 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lomustine Chemotherapy
Description: 110 mg/m2 / Q6W, oral, until progression
Study NCT00777153 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Cediranib
Description: Oral, until progression
Study NCT03780296 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real-time action observation with augmented Kinect
Description: Participants will receive 30 minutes of the augmented kinect software in real-time undergoing an exercise protocol involving seated upper extremity exercises, seated lower extremity exercises and standing upper extremity exercises.
Study NCT01214096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhNRG-1
Description: Subcutaneous Administration:0.6ug/kg/day for 10days
Study NCT01214096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhNRG-1
Description: Subcutaneous Administration 1.2ug/kg/day for 10 days
Study NCT01214096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhNRG-1
Description: Vein infusion:0.6ug/kg/day for 10 days
Study NCT01214096 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subcutaneous Administration:0.6 or 1.2ug/kg/day for 10days
Study NCT02605122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solithromycin
Study NCT02605122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Age- and weight-based dosing as appropriate per sites standard of care.
Study NCT00229385 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziprasidone
Description: 40-80 mg BID
Study NCT03340324 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V-Endo
Description: V-Endo is a tableted immunotherapeutic derived from hydrolyzed, heat-inactivated, pooled blood from women with endometriosis
Study NCT00702715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sugammadex
Description: Each subject will receive an~intravenous (i.v.) single bolus dose of 0.6 mg.kg-1 rocuronium. After~this dose, maintenance doses of 0.1 - 0.2 mg.kg-1~rocuronium may be given. In case of maintenance dosing, the target depth of~neuromuscular blockade has to be maintained at 1-2 post-tetanic counts (PTC). After the last dose of rocuronium has been administered, the subject will receive a single bolus dose of 4.0 mg.kg-1 sugammadex at a target depth of blockade of 1-2 PTC.
Study NCT00702715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sugammadex
Description: Each subject will receive an~intravenous (i.v.) single bolus dose of 0.6 mg.kg-1 rocuronium. After~this dose, maintenance doses of 0.1 - 0.2 mg.kg-1~rocuronium may be given. In case of maintenance dosing, the target depth of~neuromuscular blockade has to be maintained at 1-2 post-tetanic counts (PTC). After the last dose of rocuronium has been administered, the subject will receive a single bolus dose of 4.0 mg.kg-1 sugammadex at a target depth of blockade of 1-2 PTC.
Study NCT02641561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indomethacin
Description: Indomethacin is a non-steroidal anti-inflammatory drug (NSAID) which is commonly used to reduce inflammation caused by gout, osteoarthritis and rheumatoid arthritis. It acts by blocking the cyclo-oxygenase 1 and 2 (COX) receptors. It has also been implicated to prevent post-ERCP pancreatitis
Study NCT02641561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: Indomethacin is a non-steroidal anti-inflammatory drug (NSAID) which is commonly used to reduce inflammation caused by gout, osteoarthritis and rheumatoid arthritis. It acts by blocking the cyclo-oxygenase 1 and 2 (COX) receptors. It has also been implicated to prevent post-ERCP pancreatitis
Study NCT02641561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactated Ringer's Solution
Description: Lactated ringer's solution (LR), is an intravenous fluid (IVF) used commonly during endoscopic procedures and operative procedures. It's composition is similar to that of humans including sodium, chloride, potassium, calcium and lactate. Studies have implicated the use of this fluid in pancreatitis treatment and prevention of post-ERCP pancreatitis
Study NCT02641561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactated Ringer's Solution
Description: Lactated ringer's solution (LR), is an intravenous fluid (IVF) used commonly during endoscopic procedures and operative procedures. It's composition is similar to that of humans including sodium, chloride, potassium, calcium and lactate. Studies have implicated the use of this fluid in pancreatitis treatment and prevention of post-ERCP pancreatitis
Study NCT02641561 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: standard IVF would include 0.9% normal saline (NS) solution used during all endoscopic procedures. 0.9% NS includes equal parts sodium and chloride.
Study NCT02641561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: standard IVF would include 0.9% normal saline (NS) solution used during all endoscopic procedures. 0.9% NS includes equal parts sodium and chloride.
Study NCT02641561 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo would be a suppository 50 mg x 2
Study NCT02641561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo would be a suppository 50 mg x 2
Study NCT01258322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: The patients were randomized divided into 2 groups; one received no pioglitazone for lowing triglyceride, one with oral pioglitazone (Actos®, Takeda®) 15mg once daily for 12 weeks. After a four-week wash out, patients then continued with the alternate therapy.
Study NCT01571687 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: antioxidant supplements
Description: Intake of 6 tablets daily containing: 800 I.E. Vitamin E, 1000mg Vitamin C, 200000 I.E. Vitamin A, 600mg Acetylcystein.
Study NCT01571687 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intake of 6 identically appearing tablets daily containing placebo
Study NCT03742466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ozone
Description: After prepping and draping the area, intracarpal injection of ozone/oxygen mixture (20 ml, 25μg/ml) will be performed under sonographic guidance
Study NCT03742466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone acetate
Description: After prepping and draping the area, intracarpal injection of methylprednisolone acetate 40mg, and 40 mg lidocaine (20 ml, volume) will be performed under sonographic guidance
Study NCT02269579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-351
Study NCT01794143 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfonylurea (glimepiride)
Description: Used in accordance with labeling and/or usual practice.
Study NCT01794143 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DPP-4 inhibitor (sitagliptin)
Description: Used in accordance with labeling and/or usual practice
Study NCT01794143 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GLP-1 receptor agonist (liraglutide)
Description: Used in accordance with labeling and/or usual practice.
Study NCT01794143 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin (glargine)
Description: Used in accordance with labeling and/or usual practice.
Study NCT03206229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF
Description: PEG-rhG-CSF is going to be administered 2 mg/0.2 ml subcutaneously single dose in each study period as per the randomization schedule
Study NCT03206229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neulasta (PEG-rhG-CSF)
Description: PEG-rhG-CSF is going to be administered 2 mg/0.2 ml subcutaneously single dose in each study period as per the randomization schedule
Study NCT03805659 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HD-tDCS
Description: High-Dose transcranial Direct Current Stimulation
Study NCT03805659 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham
Description: Sham sessions (no electric current)
Study NCT04344964 — intervention group
Intervention type: OTHER
Intervention: None - NA
Description: Observational study
Study NCT02083861 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sam Ultrasonic Diathermy Device
Description: Patients apply the Sam Ultrasonic Diathermy Device daily for 4 hours of continuous therapeutic ultrasound at 3 megahertz (MHz) frequency and 0.132 Watts/cm2.
Study NCT02083861 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sam Ultrasonic Diathermy Device
Description: Patients apply the Sam Ultrasonic Diathermy Device daily for 4 hours of continuous therapeutic ultrasound at 3 megahertz (MHz) frequency and 0.132 Watts/cm2.
Study NCT01250145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY333334
Description: Transdermal patch
Study NCT01250145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Transdermal patch
Study NCT04455464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine Oral Tablet
Description: Midodrine will be given 10 mg for one time only.
Study NCT04137445 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baby Foods
Description: Commercially available baby foods
Study NCT04137445 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Foods from the home
Description: Caregiver will provide participant with usual foods from the home
Study NCT01404936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-2A
Description: 4 (x106 IU/m\^2) subcutaneously on days 1-4.
Study NCT01404936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin
Description: 25 mg/m\^2 by vein on day 4.
Study NCT01404936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Description: 10 mg/m\^2 by vein on day 4.
Study NCT01404936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velban
Description: 6 mg/m\^2 by vein on day 4.
Study NCT01404936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: 375 mg/m\^2 by vein on day 4.
Study NCT03315962 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPIRIT Intervention
Description: The intervention will include implementing a teaching collaborative among group of DHOs and TB Supervisors, enabling text messaging between DHOs and front line providers, and establishing a report collaborative where DHOs will receive feedback on the performance of their district in administering IPT compared to other districts.
Study NCT03063320 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spice blend
Description: Test spices include cardamom, coriander, cumin, ginger, paprika, red pepper, turmeric, cinnamon
Study NCT03063320 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spice blend
Description: Test spices include cardamom, coriander, cumin, ginger, paprika, red pepper, turmeric, cinnamon
Study NCT03137069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0853
Description: GDC-0853 will be administered orally at dosages of 50, 150 and 200mg to participants, as per the dosing schedules described above.
Study NCT03137069 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo will be administered orally, as per the dosing schedules described above.
Study NCT03060980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITCA 650 20/60 mcg/day
Description: ITCA 650 osmotic mini-pump delivering exenatide 20/60 mcg/day
Study NCT03060980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin (oral)
Description: 10 mg/day and 25 mg/day
Study NCT03060980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride (oral)
Description: 1-6 mg/day
Study NCT04202419 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FRAX 1940 nm laser
Description: A fractional 1940 nm solid-state diode laser will deliver linear arrays of microbeams to create nonablative microscopic treatment zones (MTZs) in the skin, in order to treat pigmented skin lesions.